United States Automated Microbial Identification Market Size & Outlook, 2026-2034
United States Automated Microbial Identification Market Insights
- According to Reed Intelligence analysis, the United States Automated Microbial Identification Market size was USD 168.35 Million in 2025 and is projected to reach USD 291.61 Million by 2034.
- The United States market is projected to grow at a CAGR of 6.31% between 2026 and 2034.
- By segment, Instruments emerged as the largest By Product Type in terms of market size in 2025.
- Consumables is anticipated to remain the most attractive By Product Type segment, recording the fastest growth during the forecast period.
![United States Automated Microbial Identification Market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/united-states-automated-microbial-identification-market-united-states-by-product-type-246267.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, United States represented 29.97% of the overall global Automated Microbial Identification Market size.
- United States is projected to lead the global Automated Microbial Identification Market size by 2034.
- Across North America, United States is anticipated to hold the dominant position in market size by 2034.
- Canada is forecasted to expand at the fastest pace in North America, attaining USD 84.98 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 168.35 Million |
| Market Size In 2034 | USD 291.61 Million |
| Largest segment | Instruments |
| Units | Revenue in USD Million |
| CAGR | 6.31% (2026-2034) |
| Segmnetation Covered | |
| By Product Type |
|
| By Technology |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Automated Microbial Identification Market By Product Type 2026-2034 (USD Million)
| By Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instruments | XX.x | XX.x | XX.x | 90.45 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Consumables | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Services | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Automated Microbial Identification Market By Technology 2026-2034 (USD Million)
| By Technology | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCR-based Systems | XX.x | XX.x | XX.x | 80.94 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Mass Spectrometry Systems | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Flow Cytometry Systems | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Automated Microbial Identification Market By End-User 2026-2034 (USD Million)
| By End-User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Laboratories | XX.x | XX.x | XX.x | 75.74 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hospitals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research and Academic Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biopharmaceutical and Biotechnology Companies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.